MC

503.1

+2.21%↑

NDA.FI

11.76

+1.2%↑

DIM

202

+1.48%↑

MC

503.1

+2.21%↑

NDA.FI

11.76

+1.2%↑

DIM

202

+1.48%↑

MC

503.1

+2.21%↑

NDA.FI

11.76

+1.2%↑

DIM

202

+1.48%↑

MC

503.1

+2.21%↑

NDA.FI

11.76

+1.2%↑

DIM

202

+1.48%↑

MC

503.1

+2.21%↑

NDA.FI

11.76

+1.2%↑

DIM

202

+1.48%↑

Search

Bayer AG

Atvērts

SektorsFinanšu

22.65 1.71

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

22.28

Max

22.665

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9B

-328M

Pārdošana

1.8B

12B

P/E

Sektora vidējais

30.9

20.525

EPS

1.05

Dividenžu ienesīgums

0.52

Peļņas marža

-2.796

Darbinieki

90,587

EBITDA

615M

1.7B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+18.73% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.52%

4.36%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-599M

21B

Iepriekšējā atvēršanas cena

20.94

Iepriekšējā slēgšanas cena

22.65

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Bayer AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. marts 09:37 UTC

Galvenie tirgus virzītāji

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

2025. g. 5. marts 11:21 UTC

Peļņas

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

2025. g. 5. marts 08:45 UTC

Peļņas

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

2025. g. 5. marts 07:26 UTC

Peļņas

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2025. g. 14. apr. 13:00 UTC

Top Ziņas

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

2025. g. 7. apr. 17:01 UTC

Tirgus saruna

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2025. g. 2. apr. 09:27 UTC

Karstas akcijas

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

2025. g. 10. marts 08:38 UTC

Tirgus saruna

Bayer's Partial Recovery Is in Sight -- Market Talk

2025. g. 5. marts 13:39 UTC

Tirgus saruna
Peļņas

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

2025. g. 5. marts 13:26 UTC

Tirgus saruna

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

2025. g. 5. marts 08:30 UTC

Tirgus saruna
Peļņas

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

2025. g. 5. marts 06:41 UTC

Peļņas

Bayer Launches Plan to Boost Profitability at Crop Science

2025. g. 5. marts 06:40 UTC

Peļņas

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

2025. g. 5. marts 06:39 UTC

Peļņas

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

2025. g. 5. marts 06:39 UTC

Peļņas

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

2025. g. 5. marts 06:36 UTC

Peļņas

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

2025. g. 5. marts 06:35 UTC

Peļņas

Bayer Guidance is on a Currency Adjusted Basis

2025. g. 5. marts 06:34 UTC

Peļņas

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

2025. g. 5. marts 06:34 UTC

Peļņas

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

2025. g. 5. marts 06:33 UTC

Peļņas

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

2025. g. 5. marts 06:33 UTC

Peļņas

Bayer Sees 2025 Sales EUR45B-EUR47B

2025. g. 5. marts 06:32 UTC

Peļņas

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

2025. g. 5. marts 06:31 UTC

Peļņas

Bayer: Analysts Saw 4Q Net Profit at EUR463M

2025. g. 5. marts 06:31 UTC

Peļņas

Bayer 4Q Net Loss EUR335M

2025. g. 5. marts 06:31 UTC

Peļņas

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

2025. g. 5. marts 06:31 UTC

Peļņas

Bayer 4Q Ebitda Before Special Items EUR2.35B

2025. g. 5. marts 06:31 UTC

Peļņas

Bayer: Analysts Saw 4Q Sales at EUR11.26B

2025. g. 5. marts 06:31 UTC

Peļņas

Bayer 4Q Sales EUR11.73B

2025. g. 13. janv. 21:05 UTC

Top Ziņas

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

2025. g. 9. janv. 15:06 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Didn't Disclose Financial Details

Salīdzinājums

Cenas izmaiņa

Bayer AG Prognoze

Cenas mērķis

By TipRanks

18.73% augšup

Prognoze 12 mēnešiem

Vidējais 26.69 EUR  18.73%

Augstākais 33 EUR

Zemākais 22 EUR

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bayer AG  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

11 ratings

1

Pirkt

10

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

21 / N/AAtbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.